Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
The chart shows the growth of an initial investment of $10,000 in Acadia Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Acadia Pharmaceuticals Inc. (ACAD) has returned -17.01% so far this year and 49.80% over the past 12 months. Looking at the last ten years, ACAD has achieved an annualized return of -2.82%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Acadia Pharmaceuticals Inc. (ACAD) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.06% | -2.89% | -8.05% | -0.09% | ||||||||
| 2025 | 1.14% | 7.34% | -15.08% | -11.84% | 47.44% | 10.48% | 9.66% | -17.89% | 6.42% | 11.29% | 7.96% | |
| 2024 | -16.66% | -10.86% | -21.39% | -10.11% | -10.33% | 7.47% | 17.48% | -13.10% | -7.13% | -4.83% | 11.32% | 12.85% |
| 2023 | 14.98% | 9.07% | -9.48% | 14.19% | 10.95% | 3.63% | 22.65% | -7.62% | -23.30% | 9.09% | -1.72% | 40.09% |
| 2022 | -3.60% | 11.59% | -0.08% | -24.02% | -11.17% | -13.24% | 4.48% | 12.84% | -0.12% | -3.55% | -3.29% | 2.05% |
| 2021 | -11.20% | 0.99% | -47.71% | -20.49% | 8.76% | 8.35% | -10.69% | -19.23% | -5.26% | 8.33% | 3.78% | 22.78% |
| 2020 | -6.83% | 5.82% | -1.08% | 17.97% | 4.88% | -2.02% | -14.76% | -5.92% | 4.27% | 12.61% | 21.85% | -6.62% |
| 2019 | 43.81% | 16.13% | 1.09% | -11.32% | -0.74% | 11.61% | -8.93% | 6.02% | 31.73% | 11.61% | 5.64% | -6.08% |
| 2018 | -1.58% | -15.86% | -11.57% | -28.69% | 14.27% | -15.77% | -0.46% | -5.14% | 46.30% | -6.44% | -3.20% | -18.00% |
| 2017 | 18.74% | 9.99% | -9.76% | -0.29% | -25.09% | 7.89% | 5.94% | 18.94% | 5.55% | -7.12% | -13.72% | -0.13% |
| 2016 | 15.90% | 3.72% | -9.41% | 14.60% | -13.14% | -1.18% | -26.23% | 15.54% | 6.46% |
The charts below present risk-adjusted performance metrics for Acadia Pharmaceuticals Inc. (ACAD) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ACAD compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Acadia Pharmaceuticals Inc. volatility is 2.74%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.56B | 748.96M | 587.81M | 700.12M | 782.62M | 783.18M | 540.20M | 384.51M | 561.15M | 221.90M | 325.46M | 189.12M | 108.59M | 32.11M |
| Equity Attributable To Parent (USD) | 1.23B | 431.76M | 400.41M | 540.89M | 627.01M | 699.14M | 479.08M | 335.29M | 518.41M | 199.76M | 309.49M | 182.13M | 84.98M | 23.36M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.23B | 431.76M | 400.41M | 540.89M | 627.01M | 699.14M | 479.08M | 335.29M | 518.41M | 199.76M | 309.49M | 182.13M | 84.98M | 23.36M |
| Noncurrent Liabilities (USD) | 59.69M | 62.95M | 61.77M | 63.16M | 49.64M | 9.22M | 1.56M | 191.00K | 157.00K | 232.00K | 135.00K | 8.00K | - | 2.59M |
| Other Current Liabilities (USD) | 220.63M | 193.99M | 84.86M | 63.30M | 71.66M | 46.52M | 39.37M | 24.98M | 24.29M | 14.51M | 9.65M | 4.74M | 4.16M | 4.21M |
| Wages (USD) | 45.58M | 42.72M | 28.02M | 25.90M | 25.81M | 21.08M | 17.03M | 15.26M | 14.38M | 5.72M | 4.17M | 1.87M | 413.00K | - |
| Accounts Payable (USD) | 10.90M | 17.54M | 12.75M | 6.88M | 8.49M | 7.22M | 3.17M | 8.79M | 3.91M | 1.67M | 2.02M | 372.00K | 1.38M | 1.96M |
| Current Liabilities (USD) | 277.11M | 254.25M | 125.63M | 96.07M | 105.97M | 74.83M | 59.57M | 49.03M | 42.59M | 21.90M | 15.83M | 6.98M | 5.95M | 6.17M |
| Liabilities (USD) | 336.81M | 317.20M | 187.40M | 159.23M | 155.61M | 84.05M | 61.12M | 49.22M | 42.74M | 22.13M | 15.97M | 6.99M | 5.95M | 8.75M |
| Other Non-current Assets (USD) | 494.57M | 128.22M | 73.85M | 74.25M | 54.73M | 17.17M | 6.73M | 2.83M | 3.16M | 704.00K | 287.00K | 179.00K | - | 14.00K |
| Intangible Assets (USD) | - | - | - | - | 1.11M | 2.59M | 4.06M | 5.54M | 7.02M | - | - | - | - | - |
| Fixed Assets (USD) | 7.51M | 4.61M | 6.02M | 8.05M | 9.16M | 3.18M | 3.31M | 2.66M | 3.08M | 2.20M | 553.00K | 579.00K | 42.00K | 151.00K |
| Noncurrent Assets (USD) | 502.08M | 132.83M | 79.88M | 82.30M | 65.00M | 22.93M | 14.10M | 11.03M | 13.26M | 2.91M | 840.00K | 758.00K | 42.00K | 165.00K |
| Other Current Assets (USD) | 891.21M | 536.59M | 474.98M | 579.83M | 682.24M | 735.30M | 501.31M | 359.77M | 543.72M | - | - | - | - | - |
| Prepaid Expenses (USD) | 59.53M | 39.09M | 21.40M | 23.89M | 25.69M | 18.61M | 20.73M | 8.46M | - | - | - | - | - | - |
| Inventory (USD) | 111.37M | 40.45M | 11.56M | 14.10M | 9.68M | 6.34M | 4.07M | 5.25M | 4.18M | - | - | - | - | - |
| Current Assets (USD) | 1.06B | 616.13M | 507.94M | 617.82M | 717.62M | 760.25M | 526.11M | 373.48M | 547.90M | 218.99M | 324.62M | 188.36M | 108.55M | 31.95M |
| Assets (USD) | 1.56B | 748.96M | 587.81M | 700.12M | 782.62M | 783.18M | 540.20M | 384.51M | 561.15M | 221.90M | 325.46M | 189.12M | 108.59M | 32.11M |
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.
The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.
The global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock. Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to ...Full story available on Benzinga.com
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?